Safety and tolerability of esketamine nasal spray versus quetiapine extended release in patients with treatment resistant depression
In ESCAPE-TRD (NCT04338321), esketamine nasal spray (NS) significantly increased the probability of remission at Week 8, and of being relapse-free through Week 32 after remission at Week 8, versus quetiapine…
Suggested reading